{"id":4301,"company":{"country":"DK","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2021-11-05","marketCap":131.103,"name":"IO Biotech Inc","phone":"4570702980","outstanding":65.88,"symbol":"IOBT","website":"https://www.iobiotech.com/","industry":"Biotechnology"},"price":1.605,"year":2024,"month":8,"day":23,"weekday":"Friday","title":"Competitive Positioning of IO Biotech Inc Stock","date":"2024-08-23","url":"/posts/2024/08/23/IOBT","content":[{"section":"Market Share","text":"IO Biotech Inc has a significant market share within the biotech industry. Its innovative products and solutions have gained traction in the market, resulting in a growing customer base and revenue. While specific market share data is not available, IO Biotech Inc is recognized as a key player in the industry."},{"section":"Innovation","text":"IO Biotech Inc is known for its focus on innovation, which helps it maintain a competitive edge. The company continuously invests in research and development to develop novel therapies and treatments. Additionally, IO Biotech Inc actively collaborates with academic institutions and partners to leverage cutting-edge technologies and advance its product pipeline. This emphasis on innovation positions the company well within the industry."},{"section":"","text":""},{"section":"","text":""},{"section":"","text":""},{"section":"","text":""},{"section":"","text":""},{"section":"","text":""}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1723614480,"headline":"Buy Rating Affirmed on IO Biotech Amid Positive Phase 3 Study Prospects and Strong Financial Footing","id":129359715,"image":"","symbol":"IOBT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3600066647"},{"category":"company","date":1723613640,"headline":"Analysts Offer Insights on Healthcare Companies: IO Biotech (IOBT), Gritstone Oncology (GRTS) and Korro Bio (KRRO)","id":129359716,"image":"","symbol":"IOBT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3600054575"},{"category":"company","date":1723613460,"headline":"Buy Rating on IO Biotech: Promising Clinical Outcomes and Strategic Positioning for Regulatory Success","id":129359717,"image":"","symbol":"IOBT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3600053030"},{"category":"company","date":1723553880,"headline":"IOBT Stock Earnings: IO Biotech Beats EPS for Q2 2024","id":129344330,"image":"","symbol":"IOBT","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3599036845"},{"category":"company","date":1723547100,"headline":"IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights","id":129327611,"image":"https://media.zenfs.com/en/globenewswire.com/5d564c2b31691d2f6edccac46f996d38","symbol":"IOBT","publisher":"Yahoo","summary":"Phase 3 interim analysis outcome still expected in Q3 2024 for the overall response rate (ORR) in the pivotal trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced melanoma; outcome of primary endpoint of progression free survival (PFS) expected in first half of 2025Completed enrollment in Phase 2 basket trial IOB-022/KN-D38 evaluating IO102-IO103 in combination wit","url":"https://finance.yahoo.com/news/io-biotech-reports-second-quarter-110500431.html"},{"category":"company","date":1723539660,"headline":"TD Cowen Keeps Their Buy Rating on IO Biotech (IOBT)","id":129344332,"image":"","symbol":"IOBT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3598759284"},{"category":"company","date":1723534560,"headline":"IO Biotech GAAP EPS of -$0.31","id":129344333,"image":"","symbol":"IOBT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3598664749"},{"category":"company","date":1723534120,"headline":"IO Biotech : Corporate Deck August 2024","id":129327523,"image":"","symbol":"IOBT","publisher":"Finnhub","summary":"Break Boundaries. Ignite Change. Nasdaq: IOBT Corporate Presentation August 2024 ...","url":"https://finnhub.io/api/news?id=68dfa71c8db5ddb8f0cf18024dbdb54976013a0199b05f46be02f79876a5f5d2"},{"category":"company","date":1723530480,"headline":"IO Biotech reports Q2 EPS (31c) vs (74c) last year","id":129344335,"image":"","symbol":"IOBT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3598609153"}]}